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bjectives This study sought to determine the efﬁcacy of high-dose atorvastatin in patients with
T-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary
ntervention (PCI).
ackground Previous randomized trials have demonstrated that statin pre-treatment reduced major
dverse cardiac events (MACEs) in patients with stable angina pectoris and acute coronary syndrome.
owever, no randomized studies have been carried out with STEMI patients in a primary PCI setting.
ethods A total 171 patients with STEMI were randomized to 80-mg atorvastatin (n  86) or
0-mg atorvastatin (n  85) arms for pre-treatment before PCI. All patients were prescribed clopi-
ogrel (600 mg) before PCI. After PCI, both groups were treated with atorvastatin (10 mg). The pri-
ary end point was 30-day incidence of MACE including death, nonfatal MI, and target vessel revas-
ularization. Secondary end points included corrected thrombolysis in myocardial infarction frame
ount, myocardial blush grade, and ST-segment resolution at 90 min after PCI.
esults MACE occurred in 5 (5.8%) and 9 (10.6%) patients in the 80-mg and 10-mg atorvastatin
re-treatment arms, respectively (p  0.26). Corrected thrombolysis in myocardial infarction frame
ount was lower in the 80-mg atorvastatin arm (26.9  12.3 vs. 34.1  19.0, p  0.01). Myocardial
lush grade and ST-segment resolution were also higher in the 80-mg atorvastatin arm (2.2  0.8
s. 1.9  0.8, p  0.02 and 61.8  26.2 vs. 50.6  25.8%, p  0.01).
onclusions High-dose atorvastatin pre-treatment before PCI did not show a signiﬁcant reduction
f MACEs compared with low-dose atorvastatin but did show improved immediate coronary ﬂow
fter primary PCI. High-dose atorvastatin may produce an optimal result for STEMI patients undergo-
ng PCI by improving microvascular myocardial perfusion. (Efﬁcacy of High-Dose AtorvaSTATIN Load-
ng Before Primary Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction [STATIN
TEMI]; NCT00808717). (J Am Coll Cardiol Intv 2010;3:332–9) © 2010 by the American College of
ardiology Foundation
rom the *Division of Cardiology, Yonsei Cardiovascular Center, Severance Hospital, Yonsei University College of Medicine,
eoul, Korea; †Division of Cardiology, Kangnam Sacred Heart Hospital, Seoul, Korea; ‡Division of Cardiology, National Health
nsurance Corporation Ilsan Hospital, Koyang, Korea; and the §Division of Cardiology, Department of Internal Medicine,
yongji Hospital, Kwandong University College of Medicine, Goyang, Korea. This study was supported in part by a grant from
he Korea Health 21 R&D Project, the Ministry of Health and Welfare and Republic of Korea (0412-CR02-0704-0001), and
rants from the Korea Healthcare Technology R&D Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea
No. A085012, A000385, and A085136), and Cardiovascular Research Center, Seoul, Korea. The first 2 authors contributed
qually to this study.anuscript received November 4, 2009, accepted November 13, 2009.
P
o
c
t
o
i
s
o
a
i
b
m
i
s
T
c
(
c
i
S
i
p
s
r
s
S
M
S
H
c
d
t
S
H
K
M
w
e
e
b
p
s
a
m
g
c
s
s
a
U
o
M
1
H
4
(
p
c
o
t
r
a
c
t
b
u
o
8
r
r
f
t
s
p
p
n
n
S
P
c
m
d
p
E
c
c
d
t
t
g
w
w
A
P
s
g
i
t
w
(
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 3 , N O . 3 , 2 0 1 0 Kim et al.
MA R C H 2 0 1 0 : 3 3 2 – 9 High-Dose Statin in STEMI
333eriprocedural myocardial injury during percutaneous cor-
nary intervention (PCI) is associated with future adverse
ardiac events (1,2). Previous clinical studies have shown
hat statin pre-treatment before PCI may improve clinical
utcomes by reducing periprocedural myocardial infarctions
n patients with stable angina pectoris or acute coronary
yndrome (ACS) (3–5). Furthermore, a recent study dem-
nstrated that reloading with high-dose statin produced an
dditional reduction of cardiovascular events after PCI, even
n patients on chronic statin therapy (6).
See page 340
However, little data exists to support statin pre-treatment
efore primary PCI in patients with ST-segment elevation
yocardial infarction (STEMI). Several observational stud-
es on patients with STEMI have suggested that previous
tatin use may improve coronary blood flow, based on
hrombolysis In Myocardial Infarction (TIMI) frame
ount after PCI, and is associated with reduced short-term
30-day) mortality (7,8). However, the beneficial effects of
hronic statin pre-treatment has limitation in its applicabil-
ty due to the unexpected nature of the onset of acute
TEMI, whereas the acute effects of high-dose statin (i.e.,
mprovement of clinical outcomes as well as coronary
erfusion) may be more clinically relevant in the emergent
etting in STEMI. Therefore, we conducted a prospective
andomized trial to determine the efficacy of high-dose
tatin immediately before primary PCI in patients with
TEMI.
ethods
tudy population. The STATIN STEMI (Efficacy of
igh-Dose AtorvaSTATIN Loading Before Primary Per-
utaneous Coronary Intervention in ST-Elevation Myocar-
ial Infarction) trial is a multicenter, randomized, prospec-
ive clinical trial conducted at 4 Korean institutions:
everance Hospital, Yonsei University of Seoul; National
ealth Insurance Corporation (NHIC) Ilsan Hospital of
oyang; Kangnam Sacred Heart Hospital of Seoul; and
yongji Hospital of Goyang (Fig. 1). Inclusion criteria
ere the presence of symptoms (12 h) and ST-segment
levation of at least 0.1 mV in 2 contiguous leads of
lectrocardiogram (ECG) or new onset left bundle branch
lock and patient age 18 to 80 years. Exclusion criteria were
revious (within 3 months) or current treatment with
tatins; known allergy to heparin, aspirin, clopidogrel, or
bciximab; active severe bleeding; pregnancy; history of
ajor surgery or trauma; significant gastrointestinal or
enitourinary bleeding (6 weeks); history of cerebrovas-
ular attack (within 2 years) or cerebrovascular attack with a
ignificant residual neurological deficit; and cardiogenic
hock with mechanical ventilation. The study protocol was tpproved by the Institutional Review Board of Yonsei
niversity College of Medicine, and written consent was
btained from all patients.
A total of 408 STEMI patients were admitted between
arch 2007 and December 2008 (Severance Hospital, n 
67; NHIC Ilsan Hospital, n 92; Kangnam Sacred Heart
ospital, n  89; and Myongji Hospital, n  60). Of the
08 patients, 159 patients were excluded due to previous
within 3 months) or current treatment with statins, 10
atients died in the emergency room (ER), 20 patients had
ardiogenic shock upon ER admission, 30 patients were
lder than 80 years, and 10 patients refused to participate in
he study. Eligible patients (n  179) were randomized to
eceive 80 or 10 mg of atorvastatin in the ER. Patients were
ssigned in a 1:1 ratio with a
omputer-generated randomiza-
ion sequence; randomization
locks were created and distrib-
ted to the 4 centers. After cor-
nary angiography, an additional
patients (4 patients in each
andomization arm) who did not
eceive angioplasty were excluded
rom the study (6 patients were
reated medically because of vaso-
pasm and 2 patients received by-
ass surgery). The remaining 171
atients (80-mg atorvastatin arm,
 86; 10-mg atorvastatin arm,
 85) were enrolled in the study.
tudy protocol and procedure.
hysicians performing the pro-
edure and the follow-up assess-
ents were blinded to the ran-
omization assignment. The
atients were pre-treated at the
R before primary PCI with
hewable aspirin (200 mg) and
lopidogrel (600-mg loading
ose). Before intervention, pa-
ients received weight-adjusted intravenous heparin with a
arget-activated clotting time of 300 s in the absence of
lycoprotein IIb/IIIa inhibitor therapy and 200 to 300 s
ith glycoprotein IIb/IIIa. Glycoprotein IIb/IIIa inhibitors
ere used during the procedure at the operator’s discretion.
ll PCIs were performed using standard technique (4).
rocedural success was defined as reduced coronary artery
tenosis to 30% residual narrowing and TIMI flow
rade 3. After PCI, aspirin (100 mg/day) was continued
ndefinitely, and clopidogrel (75 mg/day) was adminis-
ered for at least 6 months. After intervention, all patients
ere treated with the usual maintenance dose of atorvastatin
10 mg/day in Korea), irrespective of the initial randomiza-
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CK-MB  creatine kinase-
myocardial band
cTFC  corrected
thrombolysis in myocardial
infarction frame count
ECG  electrocardiogram
ER  emergency room
MACE  major adverse
cardiac event
MBG  myocardial blush
grade
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
STR  ST-segment
resolution
TIMI  Thrombolysis In
Myocardial Infarctionion assignment.
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334ngiographic and electrocardiographic analysis. Pre- and
ost-PCI angiograms were reviewed in the angiographic
ore laboratory (Cardiovascular Research Center, Seoul,
orea). The TIMI flow grade before and after PCI,
orrected TIMI frame count (cTFC), and myocardial blush
rade (MBG) were analyzed by 2 experienced observers who
ere blinded to group randomization as described previ-
usly (9–11). The ECGs before and 90 min after primary
CI were transferred to core laboratory for analysis, which was
erformed by 2 experienced physicians who were blinded to
roup randomization. Resolution of ST-segment resolution
STR) was calculated as the sum of ST-segment elevation on
nitial ECG minus the sum of ST-segment elevation on the
CG at 90 min after PCI, divided by the sum of ST-
egment elevation on initial ECG, and was expressed as a
ercentage (12). The complete early STR was defined as
70% STR.
ardiac enzyme assay. In all patients, blood samples were
ollected as possible before and at 8, 12, 24, 48, and 72 h
fter PCI to determine creatine kinase-myocardial band
CK-MB) isoenzyme elevation; further measurements were
erformed in cases of post-procedural symptoms suggestive
f myocardial ischemia. Normal limits of CK-MB and
roponin T were defined as 5 ng/ml and 0.1 g/l,
espectively. The high sensitivity C-reactive protein was
Figure 1. Study Protocol of the STATIN-STEMI Trial
Between March 2007 and December 2008, a total of 408 STEMI patients were
atorvastatin. After coronary angiography, patients who did not receive angiop
adverse cardiac event; MI  myocardial infarction; STATIN-STEMI  Efﬁcacy of
tion in ST-Elevation Myocardial Infarction; TVR  target vessel revascularizationvaluated at 24 h after primary PCI. ind points. The primary end point of the STATIN
TEMI study was the occurrence of major adverse cardiac
vents (MACEs): death, nonfatal MI (including periproce-
ural MI), and target vessel revascularization within 30 days
fter PCI. Reinfarction within 24 h of primary PCI was
efined as a re-elevation of CK-MB by at least 33% or 100%
rom the preceding nadir (which was 2 or 2 times
ormal, respectively) and reaching at least 3 times the
ormal value, in association with ischemic symptoms. After
4 h, reinfarction was defined as new pathological Q waves
r re-elevation of CK-MB to3 times the normal value (24
to discharge) or 2 times the normal value (after hospital
ischarge) (13). Target vessel revascularization included
nexpected and ischemia-driven bypass surgery or repeat
CI of the target vessels. Secondary end points of the study
ere: cTFC, MBG, and STR at 90 min after PCI.
linical follow-up. A 9-month clinical follow-up was per-
ormed for all patients to evaluate MACEs (death, nonfatal
I, and target vessel revascularization). Incidence of stent
hrombosis was also assessed according to Academic Re-
earch Consortium criteria (14).
ample size calculation and statistical analysis. Calculation
f sample size was based on a 2-sample and 2-sided test. We
ssumed the incidence of MACEs (death, nonfatal MI
ted to the ER. Eligible patients were randomized to receive 80 or 10 mg of
ere excluded from the study. ER  emergency room; MACE  major
Dose AtorvaSTATIN Loading Before Primary Percutaneous Coronary Interven-admit
lasty w
High-ncluding periprocedural MI, and target vessel revascular-
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335zation) might be similar between patients with ACS and
atients with STEMI. Therefore, we calculated a sample
ize by analogy with the ARMYDA-ACS (Atorvastatin for
eduction of MYocardial Damage During Angioplasty—
cute Coronary Syndromes) study. The difference of
ACE-free survival between treatment arms at 1 month
as 14.0%, which was also seen in the ARMYDA-ACS
tudy; MACE-free survival in the ARMYDA-ACS study
as 95.0% for high-dose (80-mg) atorvastatin arm versus
1.0% for conventional dose (10-mg) arm. Using a 2-sided
lpha level of 0.05 and statistical power of 80%, we
stimated the need for 78 patients in high-dose atorvastatin
rm and 78 patients in control arm, or a total of 170 patients
fter estimating 10% lost to follow-up.
Continuous variables were expressed as mean  SD.
omparisons of categorical variables were made using the
hi-square test and Fisher exact test, as indicated. Student t
est was used to compare continuous variables for normally
istributed values; otherwise the Mann-Whitney U test was
sed. Event-free survival analysis was analyzed by the
aplan-Meier method with log-rank test group compari-
on. Interobserver and intraobserver variability in cTFC,
BG, and STR values were assessed with 20 randomly
elected cases evaluated by 2 independent readers and by the
ame reader at 2 separate time points. Measurement varia-
ions were calculated using a linear mixed model that
ccounts for correlations between measurements obtained
rom the same patient. All analyses were performed using
he Statistical Analysis System software (SAS version 9.1.3,
AS Institute, Cary, North Carolina). A p value 0.05 was
Table 1. Baseline Demographic and Clinical Characteristics
Atorvastatin
p Value80 mg (n  86) 10 mg (n  85)
Age, yrs 61 11 59 11 0.99
Sex, M:F 66:20 66:19 0.89
Diabetes mellitus 21 (24.5) 16 (18.9) 0.47
Hypertension 45 (52.3) 39 (46.4) 0.45
Hypercholesterolemia 34 (39.5) 32 (38.1) 0.88
Current smoker 35 (40.7) 43 (50.6) 0.38
Renal insufﬁciency 8 (9.3) 3 (3.5) 0.12
Previous MI 2 (2.3) 2 (2.4) 1.00
Previous PCI 5 (5.8) 6 (7.1) 0.74
Pain-to-balloon time, min 231 167 241 158 0.56
Door–to-balloon time, min 76 44 77 39 0.40
IABP use 13 (15.1) 12 (14.1) 1.00
LVEF, % 4611 4711 0.64
Data are presented as mean SD or n (%).
IABP  intra-aortic balloon pump; LVEF  left ventricular ejection fraction; MI  myocardial
infarction; PCI percutaneous coronary intervention.onsidered statistically significant.esults
aseline characteristics. Baseline demographic and clinical
haracteristics are displayed in Table 1. Mean age was 60.3 
1.4 years and 77.2% of the patients were men. Demo-
raphic characteristics did not differ significantly between
he 2 groups. Mean left ventricular ejection fraction was
7% in all patients and did not differ between the 2 groups.
he pain-to-balloon time and door-to-balloon time were
lso not different between the 2 groups (231  167 min vs.
41 158 min, p 0.56 and 76 44 min vs. 77 39 min,
 0.40, respectively).
ngiographic and periprocedural ﬁndings. Angiographic
ndings and procedures are displayed in Tables 2 and 3.
IMI flow grade 0 before PCI was observed in 86 patients
50.6%; 80-mg atorvastatin, n  41 (48.2%); 10-mg ator-
astatin, n  45 (52.9%); p  0.66) and intracoronary
hrombi was observed in 113 patients (66.1%; 80-mg
torvastatin, n  56 (65.1%); 10-mg atorvastatin, n  57
67.1%); p  0.87). The periprocedural use of glycoprotein
Ib/IIIa inhibitor and intra-aortic balloon pump occurred in
5 cases (14.6%) and 37 patients (21.8%), respectively, with
ittle difference between the 2 groups. The proportion of
atients taking medications after PCI was also similar
etween the 2 groups. Procedural success was obtained in
56 patients (91.2%); 23 patients (80-mg atorvastatin, n 
Table 2. Baseline Periprocedural Findings and Medications
Atorvastatin
p Value80 mg (n  86) 10 mg (n  85)
Culprit lesion
Left main 0 (0) 3 (1.8) 0.24
LAD 47 (54.7) 51 (60.0) 0.24
LCx 22 (25.6) 16 (18.8) 0.24
RCA 17 (19.8) 15 (17.6) 0.24
Multivessel disease 59 (68.6) 45 (52.9) 0.04
Lesion type B2/C 83 (96.5) 76 (89.5) 0.15
TIMI ﬂow grade 0
before PCI
41 (48.2) 45 (52.9) 0.66
Intracoronary
thrombus
56 (65.1) 57 (67.1) 0.87
Bifurcation 14 (16.3) 16 (19.9) 0.62
Glycoprotein IIb/IIIa
inhibitor
20 (23.5) 17 (20.0) 0.71
IVUS use 8 (9.3) 15 (17.6) 0.12
In-hospital medication
Aspirin 86 (100) 85 (100) 1.00
Clopidogrel 86 (100) 85 (100) 1.00
Beta-blocker 69 (80.2) 65 (76.5) 0.58
ACE inhibitor or ARB 79 (91.9) 75 (88.2) 0.46
Data are presented as n (%).
ACE  angiotensin-converting enzyme; ARB  angiotensin-receptor blocker; GP  glyco-
protein; IVUS  intravascular ultrasound; LAD  left anterior descending artery; LCx  leftcircumflex artery; RCA right coronary artery; TIMI Thrombolysis In Myocardial Infarction.
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336; 10-mg atorvastatin, n  15) showed no-reflow phenom-
non after stent implantation and 15 patients (80-mg
torvastatin, n  3; 10-mg atorvastatin, n  2) fell short of
ecovering TIMI flow grade 3 after infusion of glycoprotein
Ib/IIIa inhibitor, nitrate, and nicorandil. Among 171
atients, 169 patients (98.8%) were treated with stents;
rug-eluting stents were used in 152 cases (88.9%). Mean
umber of stents per patient was 1.3; mean stent diameter
nd lengths were 3.1  0.4 and 31.0  11.6 mm, respec-
ively, which were not significantly different between the 2
roups.
rimary end point. The primary end point was evaluated 30
ays after primary PCI (Table 4). The composite primary
nd point of death, MI including periprocedural MI, and
arget vessel revascularization occurred in 5 patients (5.8%)
n the 80-mg atorvastatin arm and 9 patients (10.6%) in the
0-mg atorvastatin arm (p  0.26); no significant difference
as found between groups in overall or individual cardiac
vents. Four patients died within 30 days after PCI and all
cardiovascular event-related deaths occurred in the 10-mg
torvastatin arm. Periprocedural MI occurred in 8 patients
80-mg atorvastatin, n  3 (3.5%); 10-mg atorvastatin, n 
(5.9%); p  0.50).
econdary end points. The secondary end points are displayed
n Table 3. We found that cTFC was lower in the 80-mg
torvastatin arm (26.9 12.3 vs. 34.1 19.0, p 0.01), and
BG and STR at 90 min after primary PCI were higher in
Table 3. Angiographic and Electrocardiographic Outcomes After
Primary PCI
Atorvastatin
p Value80 mg (n  86) 10 mg (n  85)
Type of PCI
POBA 1 (1.2) 1 (1.2) 0.73
Stent 75 (98.8) 74 (98.8) 0.73
Type of stent
DES 78 (90.7) 74 (87.1) 0.73
BMS 7 (8.1) 10 (11.8) 0.73
Stent diameter, mm 3.1 0.3 3.1 0.4 0.55
Stent length, mm 30.6 11.3 31.3 11.9 0.69
Peak CK-MB, ng/dl 239 162 239 227 0.99
hsCRP, mg/l, at 24 h after PCI 4.1 7.8 7.5 22.8 0.10
TIMI ﬂow grade 3 after 83 (96.5) 76 (89.4) 0.07
TIMI blush grade 2.2 0.8 1.9 0.8 0.02
Corrected TIMI frame count 26.9 12.3 34.1 19.0 0.01
Mean ST-segment resolution 61.8 26.2 50.6 25.8 0.01
Complete ST-segment
resolution
34 (39.5) 19 (23.8) 0.03
Data are presented as n (%) or mean SD.
BMS  bare-metal stent(s); CK-MB  creatine kinase-myocardial band; DES  drug-eluting
stent(s); hsCRP high sensitivity C-reactive protein test; POBA plain only balloon angioplasty;
other abbreviations as in Tables 1 and 2.he 80-mg atorvastatin arm (MBG: 2.2  0.8 vs. 1.9  0.8, 0.02; STR: 61.8  26.2 vs. 50.6  25, p  0.01). In
ddition, complete STR (70% STR at 90 min) was also
igher in the 80-mg atorvastatin arm (34 patients [39.5%]
s. 19 patients [23.8%]; p  0.03).
Interobserver and intraobserver coefficients of variation
ssessed in 20 randomly chosen cases were 0.89 (95%
onfidence interval [CI]: 0.74 to 0.96) and 0.86 (95% CI:
.68 to 0.95) for cTFC, 0.84 (95% CI: 0.63 to 0.94) and
.80 (95% CI: 0.71 to 0.96) for MBG, and 0.98 (95% CI:
.94 to 0.99) and 0.95 (95% CI: 0.89 to 0.98) for STR,
espectively.
Peak CK-MB level did not differ between groups (239 
62 vs. 239  227; p  0.99). As for the high sensitivity
-reactive protein level at 24 h, which was somewhat lower in
he 80-mg atorvastatin arm (4.1 8.0 vs. 7.5 22.8; p 0.10).
linical outcomes. Kaplan-Meier survival curve analysis
emonstrated no significant difference in MACE-free sur-
ival at 9 months between the 2 groups (Fig. 2). Definite
tent thrombosis was observed in 1 patient in the 10-mg
torvastatin arm at 5 days after primary PCI and successfully
reated with balloon angioplasty.
iscussion
he STATIN-STEMI study is the first randomized trial to
valuate the efficacy of high-dose atorvastatin loading (80
g) before primary PCI in STEMI. Occurrence of cardiac
vents was not significantly different between the 10-mg
nd 80-mg atorvastatin pre-treatment at the 1-month and
-month clinical follow-up assessments. However, our
tudy suggested that high-dose atorvastatin loading before
CI may improve microvascular coronary perfusion as
etermined by CTFC, MBG, and STR after PCI.
The benefit of statins in primary and secondary preven-
ion for coronary artery disease is well established (15–17).
etrospective studies identified favorable effects of statin use
efore PCI as increased survival during early and interme-
iate follow-up periods as well as a reduction in periproce-
Table 4. Incidence of MACE at 30-Day Follow-Up
Atorvastatin
p Value80 mg (n  86) 10 mg (n  85)
Death 0.31
Any cause 1 (1.2) 3 (3.5)
Cardiovascular 0 (0.0) 3 (3.5)
Nonfatal MI 4 (4.7) 6 (7.1) 0.50
Periprocedural MI 3 (3.5) 5 (5.9) 0.50
TVR 0 (0.0) 1 (1.2) 0.50
MACE 5 (5.8) 9 (10.6) 0.26
Stent thrombosis 0 (0.0) 1 (1.2) 0.50
Data are presented as n (%).
MACE  major adverse cardiac event; TVR  target vessel revascularization; other abbrevia-tions as in Table 1.
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337ural MI (5,18,19). Several prospective trials have been
onducted to validate these findings of statin pre-treatment
n PCI settings. For instance, the ARMYDA trial demon-
trated an 81% risk reduction for periprocedural MI after
CI with 7-day atorvastatin pre-treatment in patients with
table angina pectoris (1). In the ARMYDA-ACS trial,
hort-term atorvastatin pre-treatment reduced the incidence
f cardiac events in patients with ACS undergoing early
CI (4).
The benefits of statin pre-treatment before PCI have
een supported with previous studies for patients with stable
ngina pectoris and ACS (unstable angina and non-
TEMI); however, only a few retrospective studies have
valuated statin pre-treatment in STEMI. Celik et al. (7)
emonstrated that previous statin use in patients with
TEMI may improve coronary blood flow after PCI,
ossibly via beneficial effects on microvascular function. Lev
t al. (8) recently reported that previous chronic statin
reatment before primary PCI reduced the 30-day short-
erm mortality (1.5% vs. 3.8%) and was an independent
redictor of 30-day mortality (odds ratio: 0.4; 95% CI: 0.13
o 0.96) after controlling for other clinical and angiographic
actors (8). However, this study was a nonrandomized study
nd assessed the effects of chronic statin therapy. As for
cute STEMI patients, application of chronic statin treat-
ent in real-world clinical practice before the occurrence of
vent is impossible as the clinical nature of STEMI is an
cute, unexpected event; therefore, we evaluated the efficacy
f acute high-dose statin for cardiac events and coronary
erfusion after primary PCI.
The STATIN-STEMI trial (3) showed no significant
Figure 2. Kaplan-Meier 9-Month MACE-Free Survival
No signiﬁcant difference in major adverse cardiac event (MACE)-free sur-
vival at 9 months was observed between the 2 groups.eduction of MACE at either 1-month or 9-month follow- cp, but the effects of high-dose atorvastatin pre-treatment
n this study could not be determined because the incidence
f clinical events was lower in both patient groups than our
riginal estimates, and thus sample size was insufficient. In
ontrast to the ARMYDA or ARMYDA-ACS trials,
eriprocedural MI was not frequently reported in the
resent study. There may be several reasons for this result:
dditional myocardial necrosis after PCI may have been
elatively smaller than the preceding, initial myocardial
ecrosis, and post-procedural MI is difficult to distinguish
rom original MI in progress. Interesting, we found that
TFC was significantly lower and MBG was higher in the
0-mg atorvastatin arm; STR at 90 min and the frequency
f complete STR were also higher in the 80-mg atorvastatin
rm.
Although these beneficial effects on myocardial perfusion
f acute high-dose statin treatment cannot be completely
xplained, this early protective effect of atorvastatin is
nlikely to be the result of cholesterol lowering. Instead,
tatins exert pleiotropic effects that may be initiated before
he lipid-lowering effects (20–22). Previous studies have
rovided evidence for beneficial effects of acute atorvastatin
reatment that may be related to lipid-independent pleio-
ropic effects such as improvement of endothelial function,
ilation of coronary microvessels (20,21), and anti-
nflammatory and antithrombotic actions (22).
Recent clinical trials have reported supportive findings for
he single high (80-mg) loading dose of atorvastatin (23).
he Naples (Novel Approaches for Preventing or Limiting
vents) II trial demonstrated that single high-dose (80-mg)
torvastatin within 24 h before PCI could improve the
linical outcomes. In addition, single high-dose statin load-
ng may be more effective in STEMI than in other clinical
ituations because STEMI is characterized by extremely
igh inflammation. The Naples II and ARMYDA-
ECAPTURE trials reported that high-dose statin was
ore effective in patients with ACS and high baseline values
n the high sensitivity C-reactive protein (6,23). Further-
ore, high-dose atorvastatin has been reported to exert
tronger anti-inflammatory and platelet inhibitory effects
han low-dose atorvastatin by reducing platelet activity and
nflammatory chemokines (24). In the present study, the
evel of high sensitivity C-reactive protein was somewhat
ower in the 80-mg atorvastatin group, consistent with
esults of the ARMYDA-ACS study, and may serve as
vidence for anti-inflammatory effects of the acute high-
ose statin used in our study.
Regarding whether sufficient time had passed for atorv-
statin to show pleiotropic effects, door-to-balloon time was
pproximately 90 min in majority of the cases. A previous
tudy by Hinoi et al. (21) demonstrated that atorvastatin
mproved blood flow within 1 h after administration,
lthough the study population exhibited no significant
oronary stenosis. Another study showed that a brief
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33810-min) exposure to atorvastatin could attenuate ischemia/
eperfusion injury when administered at the onset of reper-
usion (25). These studies may partially explain the mech-
nism for the beneficial effects of acute atorvastatin
reatment. In addition, the high dose and short action time
f atorvastatin may be another important reason for the
esults of our study. An 80-mg dose of atorvastatin is not a
ypical dose for the Korean population, who in most cases
equire dosages that are 2 times lower than those typical for
estern populations. Thus, caution should be used in
pplying the results of this study to other populations.
tudy limitations. First, the number of participants in this
tudy was not sufficient to evaluate the effects of high-dose
torvastatin on MACE because the MACE rate was much
ower than anticipated in the low-dose arm. Therefore, a
arge population study with sufficient statistical power is
eeded to confirm our findings. However, we were able to
dentify beneficial effects on myocardial perfusion using
TFC, MBG, and STR measurements. Second, serial
easurements of cardiac enzymes were not available for all
atients; only 70% of cases could be evaluated completely in
his study. Because the peak CK-MB value was missing for
ome patients, we were unable to calculate the enzymatic
nfarct size using CK-MB. Finally, although immediate
igh-dose statin loading before PCI showed beneficial
ffects on myocardial perfusion, future studies are required
o identify the mechanism behind these effects.
onclusions
ur trial shows that a high-dose atorvastatin pre-treatment
efore PCI did not show a significant reduction of MACEs,
ut was associated with improved myocardial perfusion in
atients with STEMI. Larger additional randomized stud-
es with more than 1,200 STEMI patients are needed to
onfirm these clinical benefits of high-dose statin loading in
atients who undergo primary PCI.
eprint requests and correspondence: Dr. Donghoon Choi,
ivision of Cardiology, Yonsei Cardiovascular Center, Yonsei
niversity College of Medicine, Seongsan-ro, Seodaemun-gu,
20-752 Seoul, South Korea. E-mail: cdhlyj@yuhs.ac.
EFERENCES
1. Blankenship JC, Haldis T, Feit F, et al., on behalf of REPLACE-2
Investigators. Angiographic adverse events, creatine kinase-MB
elevation, and ischemic end points complicating percutaneous cor-
onary intervention (a REPLACE-2 substudy). Am J Cardiol 2006;97:
1591–6.
2. Ricciardi MJ, Davidson CJ, Gubernikoff G, et al. Troponin I elevation
and cardiac events after percutaneous coronary intervention. Am
Heart J 2003;145:522–8.
3. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G.
Randomized trial of atorvastatin for reduction of myocardial damage
during coronary intervention: results from the ARMYDA (Atorvasta-tin for Reduction of MYocardial Damage during Angioplasty) study.
Circulation 2004;110:674–8.
4. Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves
outcomes in patients with acute coronary syndromes undergoing early
percutaneous coronary intervention: results of the ARMYDA-ACS ran-
domized trial. J Am Coll Cardiol 2007;49:1272–8.
5. Chang SM, Yazbek N, Lakkis NM. Use of statins prior to percutane-
ous coronary intervention reduces myonecrosis and improves clinical
outcome. Catheter Cardiovasc Interv 2004;62:193–7.
6. Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G,
Montinaro A. Efficacy of atorvastatin reload in patients on chronic
statin therapy undergoing percutaneous coronary intervention: results
of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of
Myocardial Damage During Angioplasty) randomized trial. J Am Coll
Cardiol 2009;54:558–65.
7. Celik T, Kursaklioglu H, Iyisoy A, et al. The effects of prior use of
atorvastatin on coronary blood flow after primary percutaneous coro-
nary intervention in patients presenting with acute myocardial infarc-
tion. Coron Artery Dis 2005;16:321–6.
8. Lev EI, Kornowski R, Vaknin-Assa H, et al. Effect of previous
treatment with statins on outcome of patients with ST-segment
elevation myocardial infarction treated with primary percutaneous
coronary intervention. Am J Cardiol 2009;103:165–9.
9. van’t Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ,
Zijlstra F. Angiographic assessment of myocardial reperfusion in
patients treated with primary angioplasty for acute myocardial infarc-
tion: myocardial blush grade. Zwolle Myocardial Infarction Study
Group. Circulation 1998;97:2302–6.
0. TIMI Study Group. The Thrombolysis in Myocardial Infarction
(TIMI) trial. Phase I findings. N Engl J Med 1985;312:932–6.
1. Gibson CM, Cannon CP, Daley WL, et al. TIMI frame count: a
quantitative method of assessing coronary artery flow. Circulation
1996;93:879–88.
2. van’t Hof AW, Liem A, de Boer MJ, Zijlstra F. Clinical value of
12-lead electrocardiogram after successful reperfusion therapy for acute
myocardial infarction. Zwolle Myocardial Infarction Study Group.
Lancet 1997;350:615–9.
3. Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-
controlled trial of platelet glycoprotein IIb/IIIa blockade with primary
angioplasty for acute myocardial infarction. ReoPro and Primary
PTCA Organization and Randomized Trial (RAPPORT) Investiga-
tors. Circulation 1998;98:734–41.
4. Mauri L, Hsieh WH, Massaro JM, Ho KK, D’Agostino R, Cutlip DE.
Stent thrombosis in randomized clinical trials of drug-eluting stents.
N Engl J Med 2007;356:1020–9.
5. Schwartz GG, Olsson AG, Ezekowitz MD, et al., on behalf of
MIRACL Study Investigators. Effects of atorvastatin on early recurrent
ischemic events in acute coronary syndromes: the MIRACL study: a
randomized controlled trial. JAMA 2001;285:1711–8.
6. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease
with pravastatin in men with hypercholesterolemia. West of Scotland
Coronary Prevention Study Group. N Engl J Med 1995;333:1301–7.
7. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering
with atorvastatin in patients with stable coronary disease. N Engl J Med
2005;352:1425–35.
8. Herrmann J, Lerman A, Baumgart D, et al. Preprocedural statin
medication reduces the extent of periprocedural non-Q-wave myocar-
dial infarction. Circulation 2002;106:2180–3.
9. Chan AW, Bhatt DL, Chew DP, et al. Early and sustained survival
benefit associated with statin therapy at the time of percutaneous
coronary intervention. Circulation 2002;105:691–6.
0. Wassmann S, Faul A, Hennen B, Scheller B, Bohm M, Nickenig G.
Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibi-
tion on coronary endothelial function. Circ Res 2003;93:e98–103.
1. Hinoi T, Matsuo S, Tadehara F, Tsujiyama S, Yamakido M. Acute
effect of atorvastatin on coronary circulation measured by transthoracic
Doppler echocardiography in patients without coronary artery disease
by angiography. Am J Cardiol 2005;96:89–91.
2. Ray KK, Cannon CP. Early time to benefit with intensive statin
treatment: could it be the pleiotropic effects? Am J Cardiol 2005;96:
54F–60F.
22
2
K
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 3 , N O . 3 , 2 0 1 0 Kim et al.
MA R C H 2 0 1 0 : 3 3 2 – 9 High-Dose Statin in STEMI
3393. Briguori C, Visconti G, Focaccio A, et al. Novel Approaches for
Preventing or Limiting Events (Naples) II trial: impact of a single high
loading dose of atorvastatin on periprocedural myocardial infarction.
J Am Coll Cardiol 2009;54:2157–63.
4. Piorkowski M, Fischer S, Stellbaum C, et al. Treatment with ezetimibe
plus low-dose atorvastatin compared with higher-dose atorvastatin
alone: is sufficient cholesterol-lowering enough to inhibit platelets?
J Am Coll Cardiol 2007;49:1035–42. a5. Bell RM, Yellon DM. Atorvastatin, administered at the onset of
reperfusion, and independent of lipid lowering, protects the myocar-
dium by up-regulating a pro-survival pathway. J Am Coll Cardiol
2003;41:508–15.
ey Words: statin  percutaneous transluminal coronary
ngioplasty  acute myocardial infarction.
